• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Immunotherapy Cancer Drugs Are Breakthrough, But Cost Is An Issue

Article

An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers and insurers will be under pressure to find savings elsewhere to pay for the high price tags of the new treatments.

Doctors at this week's annual meeting of the American Society of Clinical Oncology heard groundbreaking data on a new class of immune system boosters that some believe will become the main treatment for more than half of all cancers in the next 10 years. They included drugs from Bristol-Myers Squibb and Merck & Co that shrank tumors in patients with advanced melanoma and lung cancer.

Citigroup analysts expect such "immunotherapies" to cost around $110,000 in the United States for a year's worth of treatment and $80,000 in the rest of the world, generating sales of $35 billion a year in the next 10 years. That would represent a hefty proportion of total oncology drug sales, which research firm IMS Health has forecast reaching $88 billion by 2016.

Read the full story here: http://bit.ly/19XzxIc

Source: MedCity News

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.